Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX a randomized open-label phase 3 study

摘要

PFS in ( ) the ITT population and in patients with ( ) one prior line of therapy, ( ) responses of CR or better, ( ) prior lenalidomide exposure, or ( ) refractoriness to bortezomib. Kaplan–Meier estimates of PFS. PFS, progression-free survival; ITT, intent-to-treat; D-Rd, daratumumab/lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; HR, hazard ratio; CI, confidence interval; NE, not estimable. The upper bound of the 95% CI is currently NE.